Skip to content

Effects of Consumption of Complete Nutrition Meals with Different PFC Balance on Biological Rhythms and Visceral Fat.

Effects of Consumption of Complete Nutrition Meals with Different PFC Balance on Biological Rhythms and Visceral Fat. - Effects of Consumption of Complete Nutrition Meals with Different PFC Balance on Biological Rhythms and Visceral Fat.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050103
Enrollment
300
Registered
2024-01-23
Start date
2023-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sponsors

NISSIN FOOD PRODUCTS CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [1]Healthy Japanese males and females aged 30-64 years. [2] Individuals whose BMI is more than 23.0 kg 2 and less than 30.0 Kg 2. [3] Individuals who consume alcohol regularly in terms of frequency and quantity, and have a habit of daily consuming about 20 g/day of pure alcohol equivalent. [4]Individuals whose written informed consent has been obtained. [5]Individuals who can visit an inspection facility and be inspected in designated days. [6]Individuals judged appropriate for the study by the principal.

Exclusion criteria

Exclusion criteria: [1] Individuals who cannot continue to eat a test meal for 4 weeks. [2] Individuals whose eating habit for breakfast, lunch, and dinner is irregular and has an unbalanced diet. [3] Individuals who are in constipation. [4] Individuals using medical products. [5] Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [6] Individuals with arrhythmias including atrial fibrillation. [7] Individuals with a history of syncope. [8] Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [9] Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease. [10] Individuals who contract or have a history of serious endocrine disease. [11] Individuals with metal in their body that cannot be removed. Individuals with a cardiac pacemaker. [12] Individuals who recorded weight gain and loss (+-2 kg) in the past 1 month. [13] Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [14] Individuals who are sensitive to test product or other foods, and medical products. [15] Individuals who are undergoing dietary therapy [16] Individuals who are allergic to metals or who are at risk of developing allergies to metals [17] Individuals with possible changes of lifestyle, such as conducting a long-term travel, during the test period. [18] Individuals who have or had a habit to ingest health-promoting foods, foods for specified health uses, or health foods in the past 3 months, or will ingest those foods during the test period. [19] Individuals who are or are possibly pregnant, or are lactating. [20] Individuals who participated in other clinical studies in the past 3 months. [21] Individuals who are or whose family is engaged in health foods of functional foods. [22] Individuals judged inappropriate for the study by the principal.

Design outcomes

Primary

MeasureTime frame
[1]Indexes for biological rhythm and visceral fat (biological rhythm, stress, sleep, FatScan visceral fat area using CT scan images).

Secondary

MeasureTime frame
*Secondary indexes [1] Indexes for body composition. [2] Physical and clinical examinations. [3] Specific blood test [4] Specific fecal test [5] Specific urinary test [6] Measurement of subcutaneous fat area by FatScan using CT scan images. [7] Heart rate variability test under orthostatic load. [8] Blood glucose measurement with Free Style Libre. [9] Food frequency questionnaire:FFQ [10] State-Trait Anxiety Inventory-JYZ [11] The Japanese version of the Pittsburgh Sleep Quality Index. *Safety [1] Doctor's questions [2] Side effects and adverse events [3] Subject's diary *Other indexes [1]Evaluation of visceral fat mass area by impedance method

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp+81-3-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026